Back to search
Schizophrenia Agitation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Schizophrenia Agitation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Schizophrenia Agitation trials you may qualify forThe purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluati…
This is a single-arm pilot study to examine the impact of BXCL501 (sublingual film formulation of dexmedetomidine) administration on reducing the severity of un…
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and fema…